99mTc-interleukin-2 and (99m)Tc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease.
Crohn's disease (CD) is a chronic inflammatory bowel disease that may involve the whole gut. Marked intestinal T cell and macrophage activation is a key feature of the disease. Polymorphonuclear cell infiltration is also observed in the diseased gut, mainly during active inflammation. Scintigraphic detection of granulocytes and activated lymphocytes infiltrating the gut wall may be useful in identifying a subgroup of patients with clinically inactive CD who are undergoing early clinical relapse. The aims of the present study were (a) to compare the effectiveness of scintigraphy with (99m)Tc-labelled interleukin-2 ((99m)Tc-IL2) and with (99m)Tc-HMPAO labelled granulocytes ((99m)Tc-WBC) in detecting the presence and extent of bowel inflammation in patients with long-term inactive CD (>12 months) and (b) to assess the accuracy of these techniques in predicting future disease relapse. We studied 29 patients with ileal and/or colonic CD in stable clinical remission (Crohn's Disease Activity Index <150 for at least 12 months) using both (99m)Tc-IL2 and (99m)Tc-WBC scintigraphy in order to evaluate the extent of acute and chronic inflammation in the bowel. Planar and single-photon emission tomography images were acquired in each patient at 1 h p.i. For quantitative analysis of (99m)Tc-IL2 uptake, the abdomen was divided into 32 regions of interest. Despite the absence of symptoms, 18 patients (62%) showed a positive (99m)Tc-IL2 and 18 (62%) a positive (99m)Tc-WBC scan. Only 12 patients (41.4% of the total group) were positive on both scans, and the sites of IL2 and granulocyte bowel uptake were usually located in different segments, indicating that in CD, acute and chronic inflammation can be present in different sites. As far as the prognostic role of the two scans in predicting future disease relapse is concerned, both (99m)Tc-IL2 and (99m)Tc-WBC scintigraphy showed a high negative predictive value (1.00 and 0.91, respectively) but a weak positive predictive value (0.44 and 0.39, respectively). Nevertheless, Kaplan-Meier curves generated between scintigraphic findings and time free from disease relapse were statistically different only for (99m)Tc-IL2 scintigraphy (log-rank test, P=0.013). These results indicate that (99m)Tc-IL2 scintigraphy can be useful in selecting CD patients in clinical remission who could benefit from preventive therapy to avoid disease relapse.
Annovazzi
Alessio
A
Nuclear Medicine Unit, Department of Clinical Sciences, Policlinico Umberto I, University La Sapienza, Rome, Italy.
Biancone
Livia
L
Caviglia
Renato
R
Chianelli
Marco
M
Capriotti
Gabriela
G
Mather
Stephen J
SJ
Caprilli
Renzo
R
Pallone
Francesco
F
Scopinaro
Francesco
F
Signore
Alberto
A
D003424:Crohn Disease / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000517:prevention & control; D018572:Disease-Free Survival; D005260:Female; D006098:Granulocytes / Q000000981:diagnostic imaging*; D006801:Humans; D007376:Interleukin-2; D007422:Intestines / Q000098:blood supply / Q000000981:diagnostic imaging*; D008297:Male; D019804:Mesalamine / Q000627:therapeutic use; D008875:Middle Aged; D015609:Organotechnetium Compounds; D011237:Predictive Value of Tests; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D018570:Risk Assessment / Q000379:methods*; D055502:Secondary Prevention; D012680:Sensitivity and Specificity; D019690:Technetium Tc 99m Exametazime
D007376:Interleukin-2; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; C481016:technetium Tc 99m interleukin 2; D019690:Technetium Tc 99m Exametazime; D019804:Mesalamine